Skip to content
value.today

M3 Biotechnology, Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2011
Total raised
$103 M
2 rounds on record
Latest round
$89 M
May 2020
First round on record
Oct 2015
Today
Went public
See the company page

M3 Biotechnology, Inc. is listed today as LeonaBio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of M3 Biotechnology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$89 MNo. 2$50 to $250 million

M3 Biotechnology, Inc.: Raise no. 2, May 2020

Investors in this round

73 investors had bought by the notice of Jun 12, 2020: 73 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for M3 Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$89 M of $91 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,445,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christina M. Thomson · Executive Officer
  • Glenna M. Mileson · Executive Officer
  • Leen Kawas · Executive Officer, Director, Promoter
  • Mark M. Litton · Executive Officer
  • John M. Fluke, Jr. · Director
  • Joseph M. Edelman · Director
  • Joseph W. Harding · Director
  • Tadataka M. Yamada · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JMP Securities (CRD 22208) · San Francisco, CaliforniaSold in AK, CA, CO, GA, MA, MD, NC, NY, TX, WA

Remarks in the notice

  • On fees: “Cash fees of up to $3,455,000, plus warrants to purchase shares of Series B preferred stock at the Series B purchase price.”
  • On the amounts: “In addition to the issuance of capital stock, the Issuer issued warrants to purchase capital stock, the proceeds of which, if any, will be realized at the time of exercise.”

Signed by Leen Kawas, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 12, 2020. Read the notice at the SEC.

equity, optionsSEC
Oct 2015$14 MNo. 1$10 to $50 million

M3 Biotechnology, Inc.: Raise no. 1, Oct 2015

Investors in this round

41 investors had bought by the notice of Nov 1, 2017: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for M3 Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $17 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Fluke · Executive Officer, Director
  • Leen Kawas · Executive Officer, Director
  • Bruce Montgomery · Director
  • Joseph Harding · Director
  • Michael Montgomery · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Leen Kawas, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Nov 1, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • M3 Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

That is all the official record says: M3 Biotechnology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of M3 Biotechnology, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in M3 Biotechnology, Inc.
InvestorKindAmountRoundRoleSource
John M. Fluke Jr.Personnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Mark James LittonPersonnot statednot statedHeld Series B preferred stock (Form 3, 2020)SEC Form 3
Perceptive Advisors LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Perceptive Life Sciences Master Fund LTDFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
RTW Investments, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 73 investors.

Largest shareholders today

Institutions holding LeonaBio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by M3 Biotechnology, Inc.
NameRoleNamed in
Christina M. ThomsonExecutive officerJun 2020
Glenna M. MilesonExecutive officerJun 2020
Leen KawasExecutive officerJun 2020
Mark M. LittonExecutive officerJun 2020
John FlukeExecutive officerNov 2017
John M. Fluke, Jr.DirectorJun 2020
Joseph M. EdelmanDirectorJun 2020
Joseph W. HardingDirectorJun 2020
Leen KawasDirectorJun 2020
Tadataka M. YamadaDirectorJun 2020
Bruce MontgomeryDirectorNov 2017
John FlukeDirectorNov 2017
Joseph HardingDirectorNov 2017
Michael MontgomeryDirectorNov 2017
Leen KawasPromoterJun 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.